All News

Results from the phase 3 TRITON3 trial demonstrated that radiographic progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with rucaparib monotherapy vs physician’s choice.

A real-world study found that time to discontinuation and time to next treatment outcomes associated with ibrutinib were not impacted by a baseline high risk of atrial fibrillation or stroke in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma.

A recent analysis of data from the phase 3 PEACE-1 study reveals a correlation between 8-month prostate-specific antigen levels and survival outcomes in patients with metastatic castration-sensitive prostate cancer who are treated with systemic therapy regimens that include androgen deprivation therapy.

Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 other disease types.

Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

Treatment with gavocabtagene autoleucel demonstrated efficacy and tolerability in patients with mesothelin-expressing solid tumors, according to updated data from an ongoing phase 1/2 clinical trial.

Results from the phase 1/2 TAS-120-101 trial lead to the accelerated approval of futibatinib in patients with locally advanced or metastatic cholangiocarcinoma and an FGFR2 gene fusion or rearrangement.

Patient-reported outcome data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer.

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.

Patients with mismatch repair deficient, microsatellite instability–high advanced/recurrent endometrial cancer may derive benefit from treatment with dostarlimab-gxly.

Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.

Results from the phase 2 IMMUCHEC trial indicated that tremelimumab with or without durvalumab did not meet the primary end point of improved objective response rate vs chemotherapy in patients with treatment-naïve biliary tract cancer.

Results from a Korean study presented at 2022 IGCS showed that the level of CA-125 at different timepoints during neoadjuvant chemotherapy may help clinicians decide which patients with high-grade serous ovarian cancer should undergo interval debulking surgery.

FORE8394, which received fast track designation by the FDA, is under ongoing evaluation in a phase 1/2a trial in patients with advanced solid and central nervous system tumors harboring BRAF alterations.

Results from the phase 3 KEYLYNK-010 study showed that treatment with pembrolizumab and olaparib did not result in a statistically significant improvement in survival despite yielding higher responses compared with novel hormonal agents in patients with previously treated prostate cancer.

The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.

The Oncomine Dx Target Test was granted approval by the FDA as a companion diagnostic for RET fusion–positive thyroid cancer and RET fusion–positive non–small cell lung cancer.

A new drug application for 18F-rhPSMA-7.3 was accepted by the FDA to help with diagnostic imaging in prostate cancer.

Next-generation sequencing profiling based on cell-free DNA yielded low detection rates and concordance with tumor profiling for patients with clear cell renal cell carcinoma.

Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

Patients with locally advanced or metastatic ESR1-mutant, estrogen receptor–positive, HER2-negative breast cancer who have progressed on a CDK4/6 inhibitor may benefit from treatment with lasofoxifene and abemaciclib.

Results from a post-hoc subgroup analysis of the phase 3 TROPiCS-02 study indicated that sacituzumab govitecan improved efficacy outcomes vs physician’s choice of treatment in HER2-low and HER2 immunohistochemistry 0, hormone receptor–positive metastatic breast cancer.

An 8-to-4 vote was cast by the FDA’s Oncologic Drugs Advisory Committee against the use of duvelisib in previously treated chronic lymphocytic leukemia and small lymphocytic leukemia.

Kim Blenman, PhD, MS, discussed the promising developments in cell-counting software for predicting pathologic complete response in breast cancer.

In an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.

The FDA’s Oncologic Drugs Advisory Committee voted against poziotinib as a treatment for patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.

The FDA’s Oncologic Drugs Advisory Committee voted against continued use of melphalan flufenamide for the treatment of relapsed/refractory multiple myeloma.

At 2022 ASCO, Matthew Schabath, PhD, discussed the COLORS training designed to improve cultural sensitivity amongst oncologists treating patients within the LGBTQ+ community.